Celltrion opens world-first biosimilar symposium

Published: 2012-11-06 06:59:00

Updated: 2012-11-06 06:59:00

Celltrion, a local biopharmaceutical company, said Friday it held a launching symposium for its world’s first antibody biosimilar ‘Remsima’ at Millennium Hilton Hotel in Seoul.

Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheumatoid arthritis.
...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK